| Top Articles |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Stocks Mutual Funds > Steep Gold Price Increases Ahead - Experts Foresee $2000 Per Ounce |
|
Top Articles - Steep Gold Price Increases Ahead - Experts Foresee $2000 Per Ounce
Many investors are realizing that gold and silver now have an upside potential to appreciate that has not been seen since 1980. Similar to the situation of the late 1970’s According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product , investors are once again seeing gold coins and bullion as an important hedge against the uncertainly of war, inflation and the potential destruction of wealth due to a s ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in aky dollar. Gold’s recent performance is also attracting serious interest from investors because it has outperformed the S&P 500 index for the past five years in a row. Go lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. d and silver prices have moved steadily upward since 2001, as the value of the dollar has weakened. Many experts believe that this is a longer-term rally, which is quite y here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe ung. Robert McEwen, chairman and chief executive of a Canada-based gold mining company is very bullish on the future outlook for gold. "I expect it to test $850 by the en d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro of 2008, and by the end of 2010, north of $2,000, possibly $5,000," McEwen stated in a recent interview. Strong gold and commodity prices are spurring investment in the s ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc arch for new deposits by many mining companies across the world. His company is currently exploring for gold on mineral lands in central Nevada and expects to spend about easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi 50 million to develop the site over the coming years. Gold is seen as a profitable opportunity by many investors, having risen over 50% during the last two years, from $4 nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically 0 per ounce in May of 2005 to its current spot price of around $660. While McEwen’s price projection is considerably above the current spot gold price, he is not the only and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ndustry executive who foresees steeply increasing prices in the near future. The former CEO of a large well known US based gold mining company, Pierre Lassonde, believes g ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ld will reach $750 by Christmas of this year. In spite of the price increases in the past several years, actual production of newly mined gold from most nations continues ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a o decline, as costs rise at existing mines. In spite of the fact that gold prices have been rising toward their May 2006 peak of $725, they have failed to break above the dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod $700 mark this year, and are still seen as consolidating after the sharp run-up in prices last year. In addition, selling of the gold reserves of certain European nations, cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin most notably Spain, is seen as depressing prices in recent weeks. Silver prices have also remained strong. Many experts believe that although demand from jewelry makers w tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen ll likely drop off as gold prices rise, it is likely to be more than made up for by increased purchases from investors who are seeking a liquid investment alternative to t t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel e dollar. Investment in gold and silver for both large and small investors has been made considerably easier in recent years with the creation of Exchange Traded Funds – f ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust nds whose assets are gold or silver held in storage. That expected increase in investment demand, coupled with the declining value of the dollar, rising costs to mine gold y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products and the geopolitical risks around the globe, should tighten the supply and demand picture for the precious metal providing the driving force to move prices upward in the c . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de ming years. The author is an independent investor and not a consultant, advisor or broker. The information and opinions expressed in this article are presented for educat elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip onal purposes, and are not intended to be used as investment advice. The reader is strongly urged to fully identify and consider all the risks before making any investment tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:1 2 3 4 5 6 - Why Are There Numbers In This Title?
|